<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364309</url>
  </required_header>
  <id_info>
    <org_study_id>14438</org_study_id>
    <secondary_id>I1F-MC-RHBH</secondary_id>
    <nct_id>NCT03364309</nct_id>
  </id_info>
  <brief_title>A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis</brief_title>
  <official_title>A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 in Chinese Patients With Moderate-to-Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of the study drug&#xD;
      ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study I1F-MC-RHBH is a phase 3, multicenter, randomized, double-blind, placebo controlled,&#xD;
      parallel-group study examining the effect of 2 dose regimens of ixekizumab versus placebo in&#xD;
      participants with moderate-to-severe plaque psoriasis (Ps) during an induction dosing period&#xD;
      with dosing for 12 weeks and the primary endpoint measured at 12 weeks, followed by a&#xD;
      randomized, 48-week maintenance dosing period. During the maintenance dosing period, the&#xD;
      study will evaluate the maintenance of response/remission, as well as relapse or rebound&#xD;
      following treatment withdrawal, and response to retreatment following relapse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2018</start_date>
  <completion_date type="Actual">June 4, 2020</completion_date>
  <primary_completion_date type="Actual">June 4, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of &quot;0&quot; or &quot;1&quot; with at least a 2-point improvement from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0) (Remission)</measure>
    <time_frame>Week 12</time_frame>
    <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA assessed as 0, indicates complete resolution of plaque Ps.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction From Baseline for Participants Who Had Baseline Itch NRS ≥4</measure>
    <time_frame>Week 12</time_frame>
    <description>The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment). A score of 0 or 1 indicates no impact of disease on a participants quality of life.&#xD;
Least Square Mean (LS Mean) was calculated using Mixed Model Repeated Measures (MMRM) model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score in Participants With Baseline Fingernail Involvement</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail(fn) Ps. This scale is used to evaluate severity of fn bed Ps &amp; fn matrix Ps by area of involvement in the fn unit. fn is divided with imaginary horizontal &amp; longitudinal lines into quadrants. Each fn is given a score for fn bed Ps 0(none) to 4(Ps in 4 quadrants of the fn) &amp; fn matrix Ps 0(none) to 4(Ps in 4 quadrants in matrix), depending on presence (score of 1) or absence (score of 0) of any of the features of fn bed or matrix Ps in each quadrant.NAPSI score of a fn is sum of scores in fn bed &amp; fn matrix from each quadrant (maximum of 8). Each fn is evaluated, then the sum of all fn equals the total NAPSI score with a range from range 0 to 80. Higher scores indicate more severe ps. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb.&#xD;
LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score in Participants With Baseline Scalp Involvement</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (&lt;10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study SF-36 Mental Component Summary (MCS) Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Patient Global Assessment of Disease Severity</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Patient Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis &quot;today&quot; from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been.&#xD;
LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Palmoplantar PASI (PPASI) in Participants With Baseline Palmoplantar Involvement</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no Ps) to 72. (the most severe disease) The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on the Joint Pain Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Joint Pain VAS is a participant-administered scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of a participant's joint pain from PsA is indicated by placing a single mark on the horizontal scale (0 = none; 100 = as severe as you can imagine). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Ixekizumab Antibodies</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants * 100%.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">438</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Ixekizumab 80mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ixekizumab 80mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixekizumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Ixekizumab 80mg Q2W</arm_group_label>
    <arm_group_label>Ixekizumab 80mg Q4W</arm_group_label>
    <other_name>LY2439821</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Ixekizumab 80mg Q2W</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Present with chronic plaque Ps based on a confirmed diagnosis of chronic Ps vulgaris&#xD;
             for at least 6 months prior to baseline.&#xD;
&#xD;
          -  Have ≥10% BSA involvement at screening and baseline.&#xD;
&#xD;
          -  Have both an sPGA score ≥3 and PASI score ≥12 at screening and baseline.&#xD;
&#xD;
          -  Are candidates for phototherapy and/or systemic therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic&#xD;
             and/or guttate psoriasis) at screening or baseline.&#xD;
&#xD;
          -  Drug-induced psoriasis.&#xD;
&#xD;
          -  Ongoing use of prohibited treatments.&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study, or have previously exposed to&#xD;
             ixekizumab or any other biologic drug directly targeting interleukin-17 (IL-17) (such&#xD;
             as secukinumab) or the IL-17 receptor.&#xD;
&#xD;
          -  Have concurrent or recent use of any biologic agent within washout periods or &lt;5&#xD;
             half-lives prior to baseline, whichever is longer.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive human chorionic gonadotropin (hCG) laboratory test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Province People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YanCheng First People's Hospital</name>
      <address>
        <city>Yancheng</city>
        <state>Jiangsu</state>
        <zip>224005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Nanjing</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shan XI</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliate Hospital of Zhejiang Medical University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chao Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Dermatology Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200443</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 1, 2021</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <results_first_submitted>June 3, 2021</results_first_submitted>
  <results_first_submitted_qc>June 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2021</results_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plaque psoriasis</keyword>
  <keyword>ixekizumab</keyword>
  <keyword>skin condition</keyword>
  <keyword>skin disease</keyword>
  <keyword>itching</keyword>
  <keyword>psoriasis vulgaris</keyword>
  <keyword>immune-mediated systemic disease</keyword>
  <keyword>skin lesions</keyword>
  <keyword>scaly patches</keyword>
  <keyword>papules</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ixekizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03364309/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 27, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03364309/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Responders were defined as achieving an sPGA score of 0 or 1. Non-responders were defined as having an sPGA score of &gt;1. Responders were monitored for relapse, relapse (loss of response) occurring after Week 12 (Visit 7) was defined as an sPGA score of ≥3. In Re-treatment (Maintenance) Period, participants who relapsed received continued treatment of ixekizumab 80 mg Q4W, regardless of their treatment assignment.</recruitment_details>
      <pre_assignment_details>Induction Dosing Period: Week 0 (baseline) to Week 12. Maintenance Dosing Period and Re-treatment (Maintenance) Period: Week 12 to Week 60.&#xD;
Post-Treatment Follow-Up Period: Occurred from last treatment period visit or Early Termination Visit (ETV) up to a minimum of 12 weeks following that visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PBO-Induction Dosing Period</title>
          <description>Participants received placebo (PBO) every two weeks (Q2W) by subcutaneous (SC) injection during induction period.</description>
        </group>
        <group group_id="P2">
          <title>IXE80Q4W-Induction Dosing Period</title>
          <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab (IXE) at week 0 followed by 80mg Ixekizumab once every four weeks (80Q4W) by subcutaneous injection during induction period</description>
        </group>
        <group group_id="P3">
          <title>IXE80Q2W-Induction Dosing Period</title>
          <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (80Q2W) by subcutaneous injection during induction period</description>
        </group>
        <group group_id="P4">
          <title>IXE80Q4W(Res)/PBO-Maintenance Dosing Period</title>
          <description>Participants who received Ixekizumab 80mg Q4W in induction period and classified as responders received placebo Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="P5">
          <title>IXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing Period</title>
          <description>Participants who received Ixekizumab 80mg Q4W in induction period and classified as responders received Ixekizumab 80mg Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="P6">
          <title>IXE80Q2W(Res)/PBO-Maintenance Dosing Period</title>
          <description>Participants who received Ixekizumab 80mg Q2W in induction period and classified as responders received placebo Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="P7">
          <title>IXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing Period</title>
          <description>Participants who received Ixekizumab 80mg Q2W in induction period and classified as responders received Ixekizumab 80mg Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="P8">
          <title>PBO(Res)/PBO-Maintenance Dosing Period</title>
          <description>Participants who received placebo in induction period and classified as responders received placebo Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="P9">
          <title>PBO(NonResp)/IXE80Q4W-Maintenance Dosing Period</title>
          <description>Participants who received placebo in induction period and classified as Non-responders (NonResp) received Ixekizumab 80 mg Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="P10">
          <title>IXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing Period</title>
          <description>Participants who received Ixekizumab 80mg Q4W in induction period and classified as Non-responders received Ixekizumab 80mg Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="P11">
          <title>IXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing Period</title>
          <description>Participants who received Ixekizumab 80mg Q2W in induction period and classified as non-responders received Ixekizumab 80mg Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="P12">
          <title>PBO(Resp)/PBO-Re-treatment (Maintenance) Period</title>
          <description>Participants who were classified as placebo responders and received PBO during maintenance dosing period and after relapse retreated with Ixekizumab 80mg Q4W by SC injection.</description>
        </group>
        <group group_id="P13">
          <title>IXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) Period</title>
          <description>Participants who were classified as Ixekizumab 80mg Q4W responders and received PBO during maintenance dosing period and after relapse retreated with Ixekizumab 80mg Q4W by SC injection.</description>
        </group>
        <group group_id="P14">
          <title>IXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period</title>
          <description>Participants who were classified as Ixekizumab 80mg Q4W responders and received Ixekizumab 80mg Q4W during maintenance dosing period and after relapse received Ixekizumab 80mg Q4W by SC injection.</description>
        </group>
        <group group_id="P15">
          <title>IXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) Period</title>
          <description>Participants who were classified as Ixekizumab 80mg Q2W responders and received PBO during maintenance dosing period and after relapse retreated with Ixekizumab 80mg Q4W by SC injection.</description>
        </group>
        <group group_id="P16">
          <title>IXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period</title>
          <description>Participants who were classified as Ixekizumab 80mg Q2W responders and received Ixekizumab 80mg Q4W during maintenance dosing period and after relapse received Ixekizumab 80mg Q4W by SC injection.</description>
        </group>
        <group group_id="P17">
          <title>PBO-Follow-up Period</title>
          <description>Participants did not receive any intervention in post treatment follow-up period</description>
        </group>
        <group group_id="P18">
          <title>IXE80Q4W-Follow-up Period</title>
          <description>Participants did not receive any intervention in post treatment follow-up period</description>
        </group>
        <group group_id="P19">
          <title>IXE80Q2W-Follow-up Period</title>
          <description>Participants did not receive any intervention in post treatment follow-up period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="176"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="176"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="170"/>
                <participants group_id="P3" count="175"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">This period is to report Maintenance Period participants.</participants>
                <participants group_id="P2" count="0">This period is to report Maintenance Period participants.</participants>
                <participants group_id="P3" count="0">This period is to report Maintenance Period participants.</participants>
                <participants group_id="P4" count="47">This period is to report Maintenance Period participants.</participants>
                <participants group_id="P5" count="92">This period is to report Maintenance Period participants.</participants>
                <participants group_id="P6" count="50">This period is to report Maintenance Period participants.</participants>
                <participants group_id="P7" count="100">This period is to report Maintenance Period participants.</participants>
                <participants group_id="P8" count="3">This period is to report Maintenance Period participants.</participants>
                <participants group_id="P9" count="79">This period is to report Maintenance Period participants.</participants>
                <participants group_id="P10" count="31">This period is to report Maintenance Period participants.</participants>
                <participants group_id="P11" count="23">This period is to report Maintenance Period participants.</participants>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="92"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="100"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="79"/>
                <participants group_id="P10" count="31"/>
                <participants group_id="P11" count="23"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="80"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="84"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="73"/>
                <participants group_id="P10" count="27"/>
                <participants group_id="P11" count="17"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="46"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapsed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="45"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Re-treatment (Maintenance) Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P5" count="0">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P6" count="0">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P7" count="0">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P8" count="0">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P9" count="0">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P10" count="0">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P11" count="0">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P12" count="2">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P13" count="43">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P14" count="7">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P15" count="45">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P16" count="10">This period is to report for Re-treatment (Maintenance) Period.</participants>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="42"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="43"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-Treatment Followup Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0">This period is to report for Follow-up Period participants.</participants>
                <participants group_id="P13" count="0">This period is to report for Follow-up Period participants.</participants>
                <participants group_id="P14" count="0">This period is to report for Follow-up Period participants.</participants>
                <participants group_id="P15" count="0">This period is to report for Follow-up Period participants.</participants>
                <participants group_id="P16" count="0">This period is to report for Follow-up Period participants.</participants>
                <participants group_id="P17" count="11">This period is to report for Follow-up Period participants.</participants>
                <participants group_id="P18" count="375">This period is to report for Follow-up Period participants.</participants>
                <participants group_id="P19" count="2">This period is to report for Follow-up Period participants.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="6"/>
                <participants group_id="P18" count="344"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="5"/>
                <participants group_id="P18" count="31"/>
                <participants group_id="P19" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="3"/>
                <participants group_id="P18" count="19"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="6"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="2"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="4"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
        </group>
        <group group_id="B2">
          <title>Ixekizumab 80mg Q4W</title>
          <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
        </group>
        <group group_id="B3">
          <title>Ixekizumab 80mg Q2W</title>
          <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
            <count group_id="B2" value="174"/>
            <count group_id="B3" value="176"/>
            <count group_id="B4" value="438"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.9" spread="12.38"/>
                    <measurement group_id="B2" value="41.2" spread="11.59"/>
                    <measurement group_id="B3" value="39.2" spread="10.53"/>
                    <measurement group_id="B4" value="40.5" spread="11.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="176"/>
                    <measurement group_id="B4" value="438"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="176"/>
                    <measurement group_id="B4" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement</title>
        <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of &quot;0&quot; or &quot;1&quot; with at least a 2-point improvement from baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants with baseline sPGA &gt;=3 &amp; received at least 1 dose of study drug and had a post-baseline measurement for sPGA. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement</title>
          <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of &quot;0&quot; or &quot;1&quot; with at least a 2-point improvement from baseline.</description>
          <population>All randomized participants with baseline sPGA &gt;=3 &amp; received at least 1 dose of study drug and had a post-baseline measurement for sPGA. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.0" upper_limit="7.2"/>
                    <measurement group_id="O2" value="79.9" lower_limit="73.9" upper_limit="85.8"/>
                    <measurement group_id="O3" value="86.4" lower_limit="81.3" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>99.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>33.57</ci_lower_limit>
            <ci_upper_limit>99.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>99.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>52.49</ci_lower_limit>
            <ci_upper_limit>99.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)</title>
        <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had a post-baseline measurement for PASI 75. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)</title>
          <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had a post-baseline measurement for PASI 75. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="2.3" upper_limit="13.6"/>
                    <measurement group_id="O2" value="87.4" lower_limit="82.4" upper_limit="92.3"/>
                    <measurement group_id="O3" value="93.8" lower_limit="90.2" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>79.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.76</ci_lower_limit>
            <ci_upper_limit>99.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>99.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>64.87</ci_lower_limit>
            <ci_upper_limit>99.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0) (Remission)</title>
        <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA assessed as 0, indicates complete resolution of plaque Ps.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had a post-baseline measurement for sPGA (0). Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0) (Remission)</title>
          <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA assessed as 0, indicates complete resolution of plaque Ps.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had a post-baseline measurement for sPGA (0). Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="35.6" lower_limit="28.5" upper_limit="42.7"/>
                    <measurement group_id="O3" value="36.4" lower_limit="29.3" upper_limit="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)</title>
        <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post-baseline measurement for PASI 90. Participants who did not meet the clinical response criteria or had missing data were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)</title>
          <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post-baseline measurement for PASI 90. Participants who did not meet the clinical response criteria or had missing data were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O2" value="75.9" lower_limit="69.5" upper_limit="82.2"/>
                    <measurement group_id="O3" value="82.4" lower_limit="76.8" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>99.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.88</ci_lower_limit>
            <ci_upper_limit>99.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>99.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>46.96</ci_lower_limit>
            <ci_upper_limit>99.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)</title>
        <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had a post-baseline measurement for PASI 100. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)</title>
          <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had a post-baseline measurement for PASI 100. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="29.3" lower_limit="22.5" upper_limit="36.1"/>
                    <measurement group_id="O3" value="33.0" lower_limit="26.0" upper_limit="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction From Baseline for Participants Who Had Baseline Itch NRS ≥4</title>
        <description>The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline who had baseline Itch NRS ≥4.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction From Baseline for Participants Who Had Baseline Itch NRS ≥4</title>
          <description>The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline who had baseline Itch NRS ≥4.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="1.3" upper_limit="14.8"/>
                    <measurement group_id="O2" value="76.6" lower_limit="69.2" upper_limit="83.9"/>
                    <measurement group_id="O3" value="78.4" lower_limit="71.2" upper_limit="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>37.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.68</ci_lower_limit>
            <ci_upper_limit>99.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>41.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.09</ci_lower_limit>
            <ci_upper_limit>99.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score</title>
        <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment). A score of 0 or 1 indicates no impact of disease on a participants quality of life.&#xD;
Least Square Mean (LS Mean) was calculated using Mixed Model Repeated Measures (MMRM) model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and post baseline DLQI total score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score</title>
          <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment). A score of 0 or 1 indicates no impact of disease on a participants quality of life.&#xD;
Least Square Mean (LS Mean) was calculated using Mixed Model Repeated Measures (MMRM) model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and post baseline DLQI total score.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.495"/>
                    <measurement group_id="O2" value="-8.60" spread="0.346"/>
                    <measurement group_id="O3" value="-8.86" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-9.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.604</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.71</ci_lower_limit>
            <ci_upper_limit>-8.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-9.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.603</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.96</ci_lower_limit>
            <ci_upper_limit>-8.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score in Participants With Baseline Fingernail Involvement</title>
        <description>NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail(fn) Ps. This scale is used to evaluate severity of fn bed Ps &amp; fn matrix Ps by area of involvement in the fn unit. fn is divided with imaginary horizontal &amp; longitudinal lines into quadrants. Each fn is given a score for fn bed Ps 0(none) to 4(Ps in 4 quadrants of the fn) &amp; fn matrix Ps 0(none) to 4(Ps in 4 quadrants in matrix), depending on presence (score of 1) or absence (score of 0) of any of the features of fn bed or matrix Ps in each quadrant.NAPSI score of a fn is sum of scores in fn bed &amp; fn matrix from each quadrant (maximum of 8). Each fn is evaluated, then the sum of all fn equals the total NAPSI score with a range from range 0 to 80. Higher scores indicate more severe ps. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline fingernail involvement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score in Participants With Baseline Fingernail Involvement</title>
          <description>NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail(fn) Ps. This scale is used to evaluate severity of fn bed Ps &amp; fn matrix Ps by area of involvement in the fn unit. fn is divided with imaginary horizontal &amp; longitudinal lines into quadrants. Each fn is given a score for fn bed Ps 0(none) to 4(Ps in 4 quadrants of the fn) &amp; fn matrix Ps 0(none) to 4(Ps in 4 quadrants in matrix), depending on presence (score of 1) or absence (score of 0) of any of the features of fn bed or matrix Ps in each quadrant.NAPSI score of a fn is sum of scores in fn bed &amp; fn matrix from each quadrant (maximum of 8). Each fn is evaluated, then the sum of all fn equals the total NAPSI score with a range from range 0 to 80. Higher scores indicate more severe ps. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline fingernail involvement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="1.365"/>
                    <measurement group_id="O2" value="-11.35" spread="0.967"/>
                    <measurement group_id="O3" value="-10.07" spread="0.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-10.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.673</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.38</ci_lower_limit>
            <ci_upper_limit>-6.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-8.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.677</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.11</ci_lower_limit>
            <ci_upper_limit>-5.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis</title>
        <description>The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb.&#xD;
LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had postbaseline BSA involvement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis</title>
          <description>The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb.&#xD;
LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had postbaseline BSA involvement.</population>
          <units>Percent of BSA</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="1.660"/>
                    <measurement group_id="O2" value="-35.32" spread="1.157"/>
                    <measurement group_id="O3" value="-36.70" spread="1.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-34.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.94</ci_lower_limit>
            <ci_upper_limit>-30.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-36.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.30</ci_lower_limit>
            <ci_upper_limit>-32.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score in Participants With Baseline Scalp Involvement</title>
        <description>The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (&lt;10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline scalp involvement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score in Participants With Baseline Scalp Involvement</title>
          <description>The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (&lt;10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline scalp involvement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="0.787"/>
                    <measurement group_id="O2" value="-18.33" spread="0.544"/>
                    <measurement group_id="O3" value="-19.52" spread="0.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-16.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.957</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.62</ci_lower_limit>
            <ci_upper_limit>-14.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-17.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.954</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.80</ci_lower_limit>
            <ci_upper_limit>-16.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score</title>
        <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had post baseline SF-36 PCS score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score</title>
          <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had post baseline SF-36 PCS score.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.812" spread="0.5492"/>
                    <measurement group_id="O2" value="4.417" spread="0.3815"/>
                    <measurement group_id="O3" value="4.724" spread="0.3766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>6.228</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6681</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.915</ci_lower_limit>
            <ci_upper_limit>7.541</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>6.536</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6668</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.225</ci_lower_limit>
            <ci_upper_limit>7.847</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study SF-36 Mental Component Summary (MCS) Score</title>
        <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had post baseline SF-36 MCS score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study SF-36 Mental Component Summary (MCS) Score</title>
          <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had post baseline SF-36 MCS score.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.233" spread="0.7798"/>
                    <measurement group_id="O2" value="3.960" spread="0.5414"/>
                    <measurement group_id="O3" value="4.129" spread="0.5342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>5.193</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9489</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.328</ci_lower_limit>
            <ci_upper_limit>7.058</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>5.362</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9460</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.503</ci_lower_limit>
            <ci_upper_limit>7.222</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Patient Global Assessment of Disease Severity</title>
        <description>The Patient Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis &quot;today&quot; from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been.&#xD;
LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had postbaseline patient global assessment score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Patient Global Assessment of Disease Severity</title>
          <description>The Patient Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis &quot;today&quot; from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been.&#xD;
LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had postbaseline patient global assessment score.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.12"/>
                    <measurement group_id="O2" value="-3.1" spread="0.08"/>
                    <measurement group_id="O3" value="-3.1" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>-2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>-2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Palmoplantar PASI (PPASI) in Participants With Baseline Palmoplantar Involvement</title>
        <description>The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no Ps) to 72. (the most severe disease) The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline palmoplantar psoriasis involvement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Palmoplantar PASI (PPASI) in Participants With Baseline Palmoplantar Involvement</title>
          <description>The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no Ps) to 72. (the most severe disease) The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline palmoplantar psoriasis involvement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.99" spread="0.861"/>
                    <measurement group_id="O2" value="-6.34" spread="0.688"/>
                    <measurement group_id="O3" value="-7.78" spread="0.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-3.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.110</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.56</ci_lower_limit>
            <ci_upper_limit>-1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-4.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.064</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.90</ci_lower_limit>
            <ci_upper_limit>-2.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on the Joint Pain Visual Analog Scale (VAS)</title>
        <description>The Joint Pain VAS is a participant-administered scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of a participant's joint pain from PsA is indicated by placing a single mark on the horizontal scale (0 = none; 100 = as severe as you can imagine). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline psoriatic arthritis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on the Joint Pain Visual Analog Scale (VAS)</title>
          <description>The Joint Pain VAS is a participant-administered scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of a participant's joint pain from PsA is indicated by placing a single mark on the horizontal scale (0 = none; 100 = as severe as you can imagine). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline psoriatic arthritis.</population>
          <units>millimeter (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="9.64"/>
                    <measurement group_id="O2" value="-39.6" spread="5.48"/>
                    <measurement group_id="O3" value="-37.4" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-27.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.5</ci_lower_limit>
            <ci_upper_limit>-4.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-25.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.8</ci_lower_limit>
            <ci_upper_limit>-2.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-Ixekizumab Antibodies</title>
        <description>Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants * 100%.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80mg Q4W</title>
            <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Ixekizumab Antibodies</title>
          <description>Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants * 100%.</description>
          <population>All randomized participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 72 weeks</time_frame>
      <desc>All randomized participants who received at least one dose of study drug. Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.</desc>
      <group_list>
        <group group_id="E1">
          <title>PBO-Induction Dosing Period</title>
          <description>Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.</description>
        </group>
        <group group_id="E2">
          <title>IXE80Q4W-Induction Dosing Period</title>
          <description>Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period</description>
        </group>
        <group group_id="E3">
          <title>IXE80Q2W-Induction Dosing Period</title>
          <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period</description>
        </group>
        <group group_id="E4">
          <title>IXE80Q4W(Res)/PBO-Maintenance Dosing Period</title>
          <description>Participants who received Ixekizumab 80mg Q4W in induction period and classified as responders received placebo Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="E5">
          <title>IXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing Period</title>
          <description>Participants who received Ixekizumab 80mg Q4W in induction period and classified as responders received Ixekizumab 80mg Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="E6">
          <title>IXE80Q2W(Res)/PBO-Maintenance Dosing Period</title>
          <description>Participants who received Ixekizumab 80mg Q2W in induction period and classified as responders received placebo Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="E7">
          <title>IXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing Period</title>
          <description>Participants who received Ixekizumab 80mg Q2W in induction period and classified as responders received Ixekizumab 80mg Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="E8">
          <title>PBO(Res)/PBO-Maintenance Dosing Period</title>
          <description>Participants who received placebo in induction period and classified as responders received placebo Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="E9">
          <title>PBO(NonResp)/IXE80Q4W-Maintenance Dosing Period</title>
          <description>Participants who received placebo in induction period and classified as Non-responders received Ixekizumab 80mg Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="E10">
          <title>IXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing Period</title>
          <description>Participants who received Ixekizumab 80mg Q4W in induction period and classified as Non-responders received Ixekizumab 80mg Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="E11">
          <title>IXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing Period</title>
          <description>Participants who received Ixekizumab 80mg Q2W in induction period and classified as non-responders received Ixekizumab 80mg Q4W by SC injection in maintenance dosing period.</description>
        </group>
        <group group_id="E12">
          <title>PBO(Resp)/PBO-Re-treatment (Maintenance) Period</title>
          <description>Participants who were classified as placebo responders and received PBO during maintenance dosing period and after relapse retreated with Ixekizumab 80mg Q4W by SC injection.</description>
        </group>
        <group group_id="E13">
          <title>IXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) Period</title>
          <description>Participants who were classified as Ixekizumab 80mg Q4W responders and received PBO during maintenance dosing period and after relapse retreated with Ixekizumab 80mg Q4W by SC injection.</description>
        </group>
        <group group_id="E14">
          <title>IXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period</title>
          <description>Participants who were classified as Ixekizumab 80mg Q4W responders and received Ixekizumab 80mg Q4W during maintenance dosing period and after relapse received Ixekizumab 80mg Q4W by SC injection.</description>
        </group>
        <group group_id="E15">
          <title>IXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) Period</title>
          <description>Participants who were classified as Ixekizumab 80mg Q2W responders and received PBO during maintenance dosing period and after relapse retreated with Ixekizumab 80mg Q4W by SC injection.</description>
        </group>
        <group group_id="E16">
          <title>IXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period</title>
          <description>Participants who were classified as Ixekizumab 80mg Q2W responders and received Ixekizumab 80mg Q4W during maintenance dosing period and after relapse received Ixekizumab 80mg Q4W by SC injection.</description>
        </group>
        <group group_id="E17">
          <title>PBO-Follow-up Period</title>
          <description>Participants did not receive any intervention in post treatment follow-up period</description>
        </group>
        <group group_id="E18">
          <title>IXE80Q4W-Follow-up Period</title>
          <description>Participants did not receive any intervention in post treatment follow-up period</description>
        </group>
        <group group_id="E19">
          <title>IXE80Q2W-Follow-up Period</title>
          <description>Participants did not receive any intervention in post treatment follow-up period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="375"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Jaw cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Eyelid naevus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrosalpinx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythrodermic psoriasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="68" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="66" subjects_at_risk="100"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="58" subjects_at_risk="79"/>
                <counts group_id="E10" subjects_affected="22" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="14" subjects_at_risk="23"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E13" subjects_affected="24" subjects_at_risk="43"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="27" subjects_at_risk="45"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" subjects_affected="27" subjects_at_risk="375"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous opacities</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="174"/>
                <counts group_id="E3" events="43" subjects_affected="19" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="62" subjects_affected="17" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="64" subjects_affected="17" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="40" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E10" events="6" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E11" events="12" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="5" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" events="20" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E16" events="10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="19" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="6" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="6" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E14" events="5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" events="13" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Soft tissue inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="174"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="5" subjects_affected="5" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E10" events="5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="6" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="9" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="4" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="174"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="176"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="92"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" events="11" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="11" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="174"/>
                <counts group_id="E3" events="34" subjects_affected="28" subjects_at_risk="176"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E5" events="35" subjects_affected="25" subjects_at_risk="92"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E7" events="42" subjects_affected="31" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="24" subjects_affected="22" subjects_at_risk="79"/>
                <counts group_id="E10" events="12" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E13" events="8" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E15" events="11" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="4" subjects_affected="4" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="4" subjects_affected="4" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood immunoglobulin a increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="3" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lymphocyte count abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urine leukocyte esterase positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="3" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="6" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="8" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="174"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="176"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="10" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="12" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="5" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

